Agile Therapeutics (Agile Therapeutics) Earnings per Share (Diluted) : $-9.74 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Agile Therapeutics Earnings per Share (Diluted)?

Agile Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-1.41. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.74.

Agile Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-1.41. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.74.

Agile Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-1.37. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.69.

During the past 3 years, the average EPS without NRIGrowth Rate was 79.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 57.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 34.20% per year.

During the past 12 years, Agile Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 79.90% per year. The lowest was -11.80% per year. And the median was 17.80% per year.

Agile Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Agile Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agile Therapeutics Earnings per Share (Diluted) Chart

Agile Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-760.00

-1,220.00

-1,464.20

-58.79

-6.71

Agile Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-5.00	-5.91	-2.15	-0.27	-1.41

Competitive Comparison of Agile Therapeutics's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agile Therapeutics's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Agile Therapeutics's PE Ratio falls into.

Agile Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Agile Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-14.465	-	0)	/	2.157
	=	-6.71

Agile Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-4.47	-	0)	/	2.973
	=	-1.50

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.74

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Agile Therapeutics (OTCPK:AGRX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Agile Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Agile Therapeutics (Agile Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (OTCPK:AGRX) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 College Road East, Suite 310, Princeton, NJ, USA, 08540

Website

https://www.agiletherapeutics.com

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.

Executives

Scott M Coiante	officer: Chief Financial Officer	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Josephine Torrente	director	101 POOR FARM ROAD, PRINCETON NY 08540
Sandra Carson	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
John W Hubbard	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Amy Welsh	officer: Chief Commercial Officer	500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540
Alfred Altomari	director, officer: Chief Executive Officer	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Dennis Reilly	officer: Chief Financial Officer	600 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jason Butch	officer: Principal Accounting Officer	101 POOR FARM ROAD, PRINCETON NJ 08540
Paul Korner	officer: Sr. VP & Chief Medical Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abhijeet J Lele	director, See remarks	C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003